Obesity is a chronic, multifactorial, relapsing disease. Despite multicomponent lifestyle
interventions, including pharmacotherapy, maintaining bodyweight loss is challenging for …

Obesity is a complex, multifactorial disease that is a major public health issue worldwide.
Currently approved anti-obesity medications and lifestyle interventions lack the efficacy and …

Gut hormones secreted from enteroendocrine cells following nutrient ingestion modulate
metabolic processes including glucose homeostasis and food intake, and several of these …

The long-acting glucagon-like peptide-1 receptor (GLP1R) agonist, semaglutide and the
unimolecular glucose-dependent insulinotropic polypeptide receptor (GIPR)/GLP1R dual …

Bariatric surgery is a highly effective treatment for obesity, leading to sustained weight loss
and improvements in obesity-related comorbidities. Roux-en-Y gastric bypass (RYGB) and …

Gut peptides are small peptides secreted by gut endocrine cells that can modulate the roles
and functions of different organs through signaling. Gut peptides can also majorly impact the …

Satiety is a complex state, influenced by numerous factors that go beyond food ingestion.
Satiety influences food habits and behavior, thus affecting human health. This review …

Abstract Glucagon‐like peptide‐1 (GLP‐1) receptor agonists (GLP‐1RAs) and dual GLP‐
1/glucagon receptor agonists improve glycaemic control and cause significant weight loss in …

目前的2 型糖尿病(T2DM) 临床治疗药物种类繁多, 噻唑烷二酮类, 磺酰脲类,
双胍类及胰岛素等传统降糖药物的降糖机制与安全性存在差异. 近年来各种关于治疗T2DM …

Background & Aim: Oxyntomodulin (Oxm) is a proglucagon-derived peptide agonist of both
the GLP-1 and glucagon receptors and is a key regulator of gastric acid secretion and …